Amyloid and Tau-based therapeutics

Abstract

Alzheimer’s disease is a progressive neurodegenerative disorder characterized by declining memory, cognitive functions, and behavior. Two key pathological proteins involved are amyloid-beta (Aβ) and tau. Recent research focuses on therapies targeting these proteins, such as monoclonal antibodies like Lecanemab and Donanemab, to reduce Aβ plaques. Tau-targeted treatments aim to minimize phosphorylation or prevent tau aggregation. The presentation reviews the molecular mechanisms of Aβ and tau, emerging therapeutic strategies, recent clinical data, and challenges in safety and treatment personalization.